Trial · NCT04804605
Adverse events140
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 140
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | ARQ-151-311/312: RC/RC 0.15% Group | 18 | 439 | |
| other | COVID-19 | Infections and infestations | ARQ-151-311/312: VC/RC 0.15% Group | 12 | 218 | |
| other | COVID-19 | Infections and infestations | ARQ-151-315: RC/RC 0.05% or 0.15% Group | 13 | 382 | |
| other | COVID-19 | Infections and infestations | ARQ-151-315: VC/RC 0.05% or 0.15% Group | 5 | 180 | |
| other | Upper respiratory tract infection | Infections and infestations | ARQ-151-311/312: RC/RC 0.15% Group | 9 | 439 | |
| other | Upper respiratory tract infection | Infections and infestations | ARQ-151-311/312: VC/RC 0.15% Group | 12 | 218 | |
| other | Upper respiratory tract infection | Infections and infestations | ARQ-151-315: RC/RC 0.05% or 0.15% Group | 33 | 382 | |
| other | Upper respiratory tract infection | Infections and infestations | ARQ-151-315: VC/RC 0.05% or 0.15% Group | 16 | 180 | |
| other | Nasopharyngitis | Infections and infestations | ARQ-151-311/312: RC/RC 0.15% Group | 12 | 439 | |
| other | Nasopharyngitis | Infections and infestations | ARQ-151-311/312: VC/RC 0.15% Group | 8 | 218 | |
| other | Nasopharyngitis | Infections and infestations | ARQ-151-315: RC/RC 0.05% or 0.15% Group | 23 | 382 | |
| other | Nasopharyngitis | Infections and infestations | ARQ-151-315: VC/RC 0.05% or 0.15% Group | 5 | 180 | |
| other | Pyrexia | General disorders | ARQ-151-311/312: RC/RC 0.15% Group | 4 | 439 | |
| other | Pyrexia | General disorders | ARQ-151-311/312: VC/RC 0.15% Group | 1 | 218 | |
| other | Pyrexia | General disorders | ARQ-151-315: RC/RC 0.05% or 0.15% Group | 18 | 382 | |
| other | Pyrexia | General disorders | ARQ-151-315: VC/RC 0.05% or 0.15% Group | 10 | 180 | |
| other | Influenza | Infections and infestations | ARQ-151-311/312: RC/RC 0.15% Group | 7 | 439 | |
| other | Influenza | Infections and infestations | ARQ-151-311/312: VC/RC 0.15% Group | 3 | 218 | |
| other | Influenza | Infections and infestations | ARQ-151-315: RC/RC 0.05% or 0.15% Group | 10 | 382 | |
| other | Influenza | Infections and infestations | ARQ-151-315: VC/RC 0.05% or 0.15% Group | 11 | 180 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04804605/events